A Phase 4 Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE® (C1 Inhibitor [Human]) as Prophylactic Therapy in Subjects With Inadequately Controlled Hereditary Angioedema Attacks
收藏DataCite Commons2025-06-25 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00011166/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The objectives of the study were:1. To assess the safety and tolerability of escalating doses of CINRYZE.2. To assess the effect of an escalating dose algorithm for CINRYZE on hereditary angioedema (HAE) attack rates.3. To assess the immunogenicity of CINRYZE.
提供机构：
Vivli
创建时间：
2025-03-06
